Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
about
Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.Phenotypic and molecular detection of the bla KPC gene in clinical isolates from inpatients at hospitals in São Luis, MA, Brazil.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Establishment of Experimental Murine Peritonitis Model with Hog Gastric Mucin for Carbapenem-Resistant Gram-Negative Bacteria.The emerging threat of multidrug-resistant Gram-negative bacteria in urology.Study on MICs of Tigecycline in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae (CRE) at a Tertiary Care Centre in North India.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Multidrug-resistant bacteria in hematology patients: emerging threats.Multidrug-resistant organisms in liver transplant: Mitigating risk and managing infections.Correlation of Checkerboard Synergy Testing with Time-Kill Analysis and Clinical Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Respiratory Infections.Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.Evaluation of the RAPIDEC® CARBA NP, the Rapid CARB Screen® and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae.Surveillance of antimicrobial susceptibility patterns among Stenotrophomonas maltophilia isolated in China during the 10-year period of 2005-2014.Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.A Case of Community-Acquired Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii in Korea.
P2860
Q33555383-CF3173E1-D32E-423D-899C-E909BFCD9DB8Q35108518-6A334764-6F8D-4544-9658-469051C67B2CQ35607885-6A965C2B-01A5-4CA1-B37C-3950128E3FAEQ36215116-8781DF3B-D31F-4B48-BCE2-0E715838AA93Q37538623-10F1E266-08DD-4842-9544-8E76F21036A3Q37739009-0706BE0E-226E-4A6A-BB3D-BA5A70C077BEQ38579512-AC5952F7-32DF-485F-A2B4-4938C0CF3395Q38782367-15433E5D-EE01-4074-8984-EC8F23A62FE6Q38783043-08D59FB6-BA3D-4001-8F91-355D1FEB1944Q38838498-54A05355-5063-41D4-A6C6-56B11E14E2B2Q38845084-6E3B9E4C-F336-46DF-8478-4160818F0499Q40575107-930A594C-F798-4E34-9663-383171B3A7EBQ40967518-A1390818-1763-4D94-A49D-90DCEDC59ADCQ41060492-7D2250A1-F623-43A5-9E50-960B2E68A0ECQ41994109-03B972C0-EC20-428F-9C5D-96EF4B2122CCQ47206190-E59DD4AD-2DA1-450A-948F-DF6C2A730825Q47656109-F7D73353-44EF-4547-B80A-E16232F00D3FQ47691167-458E4394-C4BD-462E-968F-37AAC9409F7CQ48311635-E2D785D8-98E7-4062-95B5-9CC567E80FAF
P2860
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@ast
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@en
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@nl
type
label
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@ast
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@en
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@nl
prefLabel
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@ast
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@en
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@nl
P2860
P356
P1476
Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens
@en
P2093
Chang-Seop Lee
P2860
P304
P356
10.3947/IC.2014.46.3.149
P50
P577
2014-09-24T00:00:00Z